ReviewInternational journal of molecular sciences2020
MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Discovering diabetes complications-related microRNAs: meta-analyses and pathway modeling approach.BMC medical genomics · 2025Pooled it
- Therapeutic Mechanisms of Stem Cell-Derived Exosomes for Neurological Disorders: An Overview.Molecular neurobiology · 2026Review
- Potential of circulating miR-29a and miR-142-5p as biomarkers for diabetic nephropathy: a cross-sectional study.Frontiers in medicine · 2026Article
- lncRNAs and circRNAs: Emerging Players in Pediatric Medulloblastoma Pathology.Current medicinal chemistry · 2026Review
- Correction: Beylerli et al. MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.International journal of molecular sciences · 2025Article
- Liquid Biopsy in Pituitary Neuroendocrine Tumors-Potential Biomarkers for Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2025Review
- Metformin induces apoptosis in pituitary-derived folliculostellate cells via the IL-6/ERK pathway.Discover oncology · 2025Article
- Targeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma.Non-coding RNA research · 2025Review
- New approaches to targeted drug therapy of intracranial tumors.Cell death discovery · 2025Review
- Exosomal CircMFN2 Enhances the Progression of Pituitary Adenoma via the MiR-146a-3p/TRAF6/NF-κB Pathway.Journal of neurological surgery. Part A, Central European neurosurgery · 2025Article
- Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Article
- MicroRNAs in meningiomas: Potential biomarkers and therapeutic targets.Non-coding RNA research · 2024Review
- From bench to bedside: The promising value of exosomes in precision medicine for CNS tumors.Heliyon · 2024Review
- Recent Advances in Therapeutic Modalities Against Breast Cancer-Related Lymphedema: Future Epigenetic Landscape.Lymphatic research and biology · 2023Review
- Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.Cancers · 2023Review
- Regulation of long noncoding RNAs in the pathogenesis and clinical implications of pituitary adenomas.Immunity, inflammation and disease · 2023Review
- Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.Journal of endocrinological investigation · 2023Article
- The Role of Mitochondria-Targeting miRNAs in Intracerebral Hemorrhage.Current neuropharmacology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
Pituitary adenoma (PA) accounts for 10-15% of all intracranial neoplasms. Even though most pituitary adenomas are benign, it is known that almost 35% of them exhibit an aggressive clinical course, including rapid proliferative activity and invasion of neighboring tissues. MicroRNAs (miRNAs) are short single-stranded RNA molecules that can influence post-transcriptional regulation by controlling target genes. Based on research data on miRNAs over the past 20 years, more than 60% of genes encoding human proteins are regulated by miRNAs, which ultimately control basic cellular mechanisms, including cell proliferation, differentiation, and apoptosis. Dysregulation of miRNAs has been observed in a number of diseases, especially tumors like PA. A majority of miRNAs are expressed within the cells themselves. However, the circulating miRNAs can be detected in several biological fluids of the human body. The identification of circulating miRNAs as new molecular markers may increase the ability to detect a tumor, predict the course of a disease, plan to choose suitable treatment, and diagnose at the earliest signs of impending neoplastic transformation. Therapy of PAs with aggressive behavior is a complex task. When surgery and chemotherapy fail, radiotherapy becomes the treatment of choice against PAs. Therefore, the possibility of implementing circulating miRNAs as innovative diagnostic and therapeutic agents for PA is one of the main exciting ideas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.